Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Eli Lilly hikes sales guidance by $2bn, shares jump
(Sharecast News) - Shares in Eli Lilly jumped on Wall Street on Tuesday after the American pharma giant beat quarterly profit forecasts and hiked its full-year sales guidance by $2bn, helped by surging demand for its weight-loss drug Zepbound. The company is now guiding to full-year revenues of $42.4bn-$43.6bn, from $40.4bn-$41.6bn previously, while earnings per share guidance has been hiked to $13.05-13.55, from $11.80-12.30 previously.
The consensus estimate prior to Tuesday's results was for group revenues of $41.4bn and earnings of $12.50 a share.
The upgrade was driven by strong performances of Zepbound and diabetes drug Mounjaro along with greater visibility into production expansion for the remainder of the year, with both drugs currently in short supply in the US market.
Mounjaro sales jumped to $1.81bn in the period, up from $569m the year before, while Zepbound - which only launched in November 2023 - generated revenue of $517m.
Eli Lilly reported first-quarter revenues of $8.77bn, up 26% year-on-year, while earnings per share surged 59% to $2.58. While sales came in slightly short of the $8.92bn market forecasts, earnings beat the $2.46 estimate.
"Our progress in addressing some of the world's most significant health care challenges has resulted in increased demand for our medicines," said chief executive and chair David Ricks.
"As we continue to make pipeline investments that position us for future growth, we are rapidly expanding manufacturing capacity to make our incretin medicines available to more patients."
The stock was up 6.3% at $783.30 by 1047 in New York.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.